bioAffinity Technologies Reports Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

Company streamlines operations to focus on profitable diagnostic testing services including CyPath® Lung, driving 87% revenue increase and 99% unit sales growth

Mar. 13, 2026 at 1:07pm

Got story updates? Submit your updates here. ›

bioAffinity Technologies, Inc., a biotechnology company focused on noninvasive, accurate tests for early-stage lung cancer and other lung diseases, reported record revenue and unit sales in 2025 for its flagship product CyPath® Lung. The company streamlined operations to focus on profitable diagnostic testing services, leading to a 87% increase in CyPath® Lung revenue and a 99% increase in the number of tests performed compared to 2024. Orders for CyPath® Lung by physicians and clinics rose 67% year-over-year due to peer-to-peer marketing, positive real-world experiences, and growing test awareness.

Why it matters

CyPath® Lung is a noninvasive diagnostic test that provides clinical confidence for physicians and better outcomes for patients at risk of lung cancer. The strong growth in revenue and unit sales validates the company's commercialization strategy and highlights the increasing demand for accurate, early-stage lung cancer detection tools, particularly as the number of indeterminate pulmonary nodules detected through screening is projected to grow significantly in the coming years.

The details

bioAffinity Technologies discontinued unprofitable pathology services and reallocated resources to the commercialization of CyPath® Lung, leading to a 34% decrease in total revenue but a 9% decrease in operating expenses compared to 2024. The number of physician offices and clinics ordering CyPath® Lung increased 67% over 2024, and the company expects this trend to accelerate as it expands its sales force into new markets. Peer-to-peer physician engagement, compelling patient case studies, and key opinion leaders sharing their clinical experience have been key drivers of CyPath® Lung's growing awareness and adoption.

  • In 2025, revenue from CyPath® Lung increased 87% over 2024.
  • The number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024.
  • Orders for CyPath® Lung by physicians and clinics rose 67% year-over-year in 2025.

The players

bioAffinity Technologies, Inc.

A biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases.

Gordon Downie, MD, PhD

Joined bioAffinity Technologies as Chief Medical Officer, bringing more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role.

Roberto Rios, CPA

Appointed to the Board of Directors in 2025, with more than four decades of executive leadership experience in corporate finance and governance across industries including biotechnology and medical devices.

John J. Oppenheimer, MD

Appointed to the Board of Directors in 2025, a recognized leader in the diagnosis and treatment of asthma and COPD who directs clinical research in lung health and teaches at the University of Medicine and Dentistry of New Jersey-Rutgers.

Maria Zannes

bioAffinity President and Chief Executive Officer.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a transformational year for bioAffinity Technologies. We took deliberate actions to streamline operations at PPLS and align our resources behind the national expansion of CyPath® Lung.”

— Maria Zannes, bioAffinity President and Chief Executive Officer

“Every day, we hear from practitioners who confirm the need for noninvasive, accurate lung cancer diagnostics, particularly when imaging and risk models are inconclusive or turn out to be wrong. CyPath® Lung remains our first priority. It is a gamechanger that provides clinical confidence for physicians and better outcomes for patients.”

— Maria Zannes, bioAffinity President and Chief Executive Officer

What’s next

In March 2026, bioAffinity enrolled the first patient in a longitudinal study evaluating CyPath® Lung as a noninvasive diagnostic for high-risk patients with indeterminate pulmonary nodules. The trial plans to enroll up to 2,000 patients across 17 Veterans Administration (VA), military, academic, and private medical centers and will assess the sensitivity and specificity of the test over a follow-up period of up to two years.

The takeaway

bioAffinity's focus on improving care for patients at risk for lung cancer and other pulmonary diseases through its innovative CyPath® Lung diagnostic has positioned the company for continued growth and long-term value creation. The strong performance of CyPath® Lung in 2025, driven by increased physician adoption and clinical utilization, demonstrates the potential for noninvasive, accurate lung cancer testing to transform patient outcomes.